Clinical Trials at Sanford Stem Cell Clinical Center

CIRM Alpha Stem Clinic at UC San Diego Health

Select a study to learn more:

Spinal Cord Injury

Researchers at UC San Diego Health are collaborating with Neuralstem, Inc. to conduct a safety trial of a human spinal cord-derived neural stem cell line in people with paralysis due to a spinal cord injury. 

This clinical trial evaluates the safety of transplanting neural stem cells into the spine.

Eligibility and More Information


Chronic Lymphocytic Leukemia

Researchers at UC San Diego Health are collaborating with Oncternal Therapeutics, Inc. to evaluate the effectiveness of the ROR1-targeting monoclonal antibody, cirmtuzumab, when given in combination with a BTK inhibitor, ibrutinib, in people with chronic lymphocytic leukemia, small lymphocytic leukemia or mantle cell lymphoma. 

Eligibility and More Information


Type 1 Diabetes

Researchers at UC San Diego Health are collaborating with ViaCyte, Inc. to conduct a Phase I/II clinical trial of a combination product to treat people with type 1 diabetes and hypoglycemia unawareness.

The therapy involves implanting a device containing cells under the skin. This clinical trial evaluates the safety, tolerability and effectiveness of the combination product.

Eligibility and More Information


Chronic Heart Failure

Researchers at UC San Diego Health are collaborating with Mesoblast, Ltd. to conduct a Phase III clinical trial of bone marrow-derived mesenchymal precursor cell (MPC) transplantation in people with chronic heart failure due to LV systolic dysfunction.

This study evaluates the effectiveness of transplanting bone marrow-derived allogeneic MPCs to treat chronic heart failure.

Eligibility and More Information


Myelodysplastic Syndromes

Researchers at UC San Diego Health are collaborating with Mesoblast, Ltd. to conduct a Phase III clinical trial of bone marrow-derived mesenchymal precursor cell (MPC) transplantation in people with chronic heart failure due to LV systolic dysfunction.

This study evaluates the effectiveness of transplanting bone marrow-derived allogeneic MPCs to treat chronic heart failure.

Eligibility and More Information


Degenerative Disc Disease

Researchers at UC San Diego Health are collaborating with DiscGenics, Inc. to conduct a Phase I/II clinical trial of an allogeneic cell therapy, administered via injection, in people with chronic low back pain due to degenerative disc disease at a single lumbar level.

Eligibility and More Information


Breast Cancer

Researchers at UC San Diego Health are collaborating with Oncternal Therapeutics, Inc. to evaluate the effectiveness of the ROR-1 targeting monoclonal antibody, cirmtuzumab, when given in combination with paclitaxel in people with HER2 negative, metastatic breast cancer.

Cirmtuzumab is an investigational drug that is designed to attach to a protein called ROR-1 and block the growth and survival of breast cancer cells.

Eligibility and More Information